1 |
Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae |
|
|
| Xi-Wei Ji, Xiao Zhu, Yun Li, Feng Xue, Isabelle Hui San Kuan, Qing-Feng He, Xiang-Rui Meng, Xiao-Qiang Xiang, Yi-Min Cui, Bo Zheng |
|
| Frontiers in Pharmacology. 2022; 13 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
2 |
Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease |
|
|
| Chien-Ming Chao, Chih-Cheng Lai, Chen-Hsiang Lee, Hung-Jen Tang |
|
| Antibiotics. 2022; 11(5): 610 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
3 |
Therapeutic Effectiveness of Cefoperazone for Community-Acquired Pneumonia and Associated Factors in a Tertiary Care Hospital, Vietnam |
|
|
| Cua Ngoc Le, Duong Trung Nguyen, Supreecha Kaewsawat, Charuai Suwangbamrung, Patthanasak Khammaneechan |
|
| Journal of Pharmacy and Nutrition Sciences. 2021; 11: 20 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
4 |
Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients |
|
|
| Chun-Ta Huang, Chia-Hung Chen, Wei-Chih Chen, Yao-Tung Wang, Chih-Cheng Lai, Pin-Kuei Fu, Li-Kuo Kuo, Chin-Ming Chen, Wen-Feng Fang, Chih-Yen Tu, Shih-Chi Ku |
|
| International Journal of Antimicrobial Agents. 2021; : 106491 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
5 |
Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria? |
|
|
| Yee-Huang Ku,Wen-Liang Yu |
|
| Infection, Genetics and Evolution. 2021; : 104707 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
6 |
Clinical Efficacy and Safety of Cefoperazone–Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis |
|
|
| Shao-Huan Lan,Chien-Ming Chao,Shen-Peng Chang,Li-Chin Lu,Chih-Cheng Lai |
|
| Surgical Infections. 2021; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
7 |
In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products |
|
|
| Ming-Jen Sheu,Chi-Chung Chen,Ying-Chen Lu,Bo-An Su,Chun-Cheng Zhang,Shu-Shen Wang,Yin-Ching Chuang,Hung-Jen Tang,Chih-Cheng Lai |
|
| Antibiotics. 2020; 9(2): 77 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
8 |
Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia |
|
|
| Jien-Wei Liu,Yen-Hsu Chen,Wen-Sen Lee,Jung-Chung Lin,Ching-Tai Huang,Hsi-Hsun Lin,Yung-Ching Liu,Yin-Ching Chuang,Hung-Jen Tang,Yao-Shen Chen,Wen-Chien Ko,Min-Chi Lu,Fu-Der Wang |
|
| Antimicrobial Agents and Chemotherapy. 2019; 63(8) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
9 |
The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms |
|
|
| Ping-Chin Chang,Chi-Chung Chen,Ying Chen Lu,Chih-Cheng Lai,Hui-Ling Huang,Yin-Ching Chuang,Hung-Jen Tang |
|
| Journal of Microbiology, Immunology and Infection. 2017; |
|
| [Pubmed] [Google Scholar] [DOI] |
|